Acapedia

Cytology has always been powerful for early cancer detection — but limited by subjective interpretation.

A new study in Nature introduces a clinical-grade autonomous cytopathology system that combines:

• Whole-slide 3D edge tomography

• Real-time compression + edge computing

• End-to-end AI cell detection and classification

• Population-level morphological profiling (CMD framework)

Results show >0.99 AUC at single-cell level and strong multicentre slide-level performance across 1,100+ samples.

This is not just “AI assistance.”

It’s a step toward fully autonomous, scalable, and objective cytology workflows.


The real question:

Are we ready to trust autonomous triage in routine cancer screening?

https://www.nature.com/articles/s41586-025-10094-y

Clinical-grade autonomous cytopathology through whole-slide edge tomography - Nature This study presents a clinical-grade autonomous pipeline combining high-resolution whole-slide tomography, edge computing and artificial intelligence, achieving high accuracy in cervical cytology and enabling scalable and objective diagnostics.

🧠 Why Hesitation Isn’t Weakness—It’s a Brain Feature

A new study published in Nature Neuroscience (2025) reveals that hesitation—the brief pause before acting under uncertainty—is not a failure of decision-making, but an actively regulated neural process.

In “The striatal indirect pathway mediates hesitation”, MATTHEW A GERAMITA, Susanne Ahmari, and Eric Yttri demonstrate that neurons in the indirect pathway of the dorsomedial striatum specifically control hesitation when outcomes are uncertain. Importantly, this mechanism is distinct from the brain circuits that drive action.

🔬 Key takeaways:

- Hesitation increases only under uncertainty, not predictable outcomes

- The indirect pathway suppresses action to prevent costly mistakes

- Optogenetic activation increases hesitation; silencing removes it

- Hesitation is purposeful, adaptive, and precisely timed

🏒⛷️ Why it matters beyond the lab

From Olympic athletes timing a perfect start, to firefighters making split-second decisions, to everyday choices under uncertainty—this neural system helps balance impulsivity and restraint.

These findings also have implications for conditions involving disrupted timing and control, including anxiety disorders, OCD, and Tourette syndrome.

This work reframes hesitation not as something to eliminate, but something to calibrate.

📖 Published in Nature Neuroscience

https://www.nature.com/articles/s41593-025-02135-6

The striatal indirect pathway mediates hesitation - Nature Neuroscience Hesitation—pausing in the face of uncertainty—is ubiquitous in daily life and disrupted in several psychiatric disorders. Unlike other forms of response inhibition, hesitation is mediated by indirect, but not direct, pathway striatal neurons.

🎓 1.0 CME Credit | Breast Imaging & Elastography

This article is available for 1.0 CME credit and reviews the diagnostic value of the elastography strain rate (SR) ratio in differentiating benign and malignant BI-RADS-US 3–4 breast masses.

📊 Key learning points:

• Optimal SR cut-off value: 3.57

• Sensitivity: 85.7%

• Specificity: 98.8%

• Diagnostic accuracy: 93.6%

• Excellent agreement with pathology (κ = 0.864)

• Strong diagnostic performance across BI-RADS categories

(AUC range: 0.793–0.985)

🔍 The study demonstrates how quantitative elastography can enhance diagnostic confidence, particularly in the challenging BI-RADS 3–4 spectrum, and serves as a valuable CME learning resource for breast imaging professionals.

🩻 Specialty: Radiology – Breast Imaging

🎯 Focus: Elastography, elasticity imaging techniques

🎓 CME Credit: 1.0

https://www.acapedia.com/article/elastography-strain-ratio-bi-rads-breast-masses

Acapedia CME | Elastography in BI-RADS 3-4 Breast Mass Diagnostics Earn CME credits with Acapedia! Delve into our comprehensive study on the diagnostic value of elastography strain rate in BI-RADS 3-4 breast masses. Start learning now!

Dual gene deletion reveals potential biomarkers for predicting immunotherapy success

Why do some tumors respond dramatically to immunotherapy while others remain resistant?

This study from the Wellcome Trust Sanger Institute, in collaboration with Open Targets and the Netherlands Cancer Institute, provides a compelling answer by uncovering tumor-intrinsic genetic factors that shape immune response.

What’s new in the approach

◉ Genome-wide CRISPR-Cas9 screens performed under immune selection

◉ A novel tumor–immune co-culture system, combining patient-derived tumor cells with autologous T cells

◉ Direct measurement of immune-mediated cancer cell killing

Key insights

◉ Loss of CHD1 or MAP3K7 (TAK1) makes cancer cells significantly more sensitive to immune attack

◉ Dual loss amplifies this effect, particularly under IFN-γ signaling and T cell pressure

◉ In mouse models, tumors lacking these genes show stronger responses to immune checkpoint blockade (ICB) and increased infiltration of cytotoxic T cells

◉ Analysis of patient data reveals that low CHD1 or MAP3K7 expression correlates with better clinical response to immunotherapy

These findings position CHD1 and MAP3K7 as promising biomarkers for predicting which patients are most likely to benefit from immunotherapy — and point toward new strategies for personalized cancer treatment.

Authors:

Alex Watterson, Gabriele Picco, Vivien Veninga, Youhani Samarakoon, PhD, Chiara M. Cattaneo, Sara F. Vieira, Emre Karakoc, Shriram Bhosle, Thomas W. Battaglia, Sarah Consonni, Timotheus You Fu Halim, Emile Voest, Mathew Garnett, Matthew Coelho

https://www.sciencedirect.com/science/article/pii/S266637912500638X?via%3Dihub

www.sciencedirect.com

1.0 CME Opportunity | ¹⁸F-FDG PET/CT in Head and Neck Squamous Cell Carcinoma

This publication is available as a 1.0 CME-accredited educational activity, making it a strong option for clinicians looking to combine continuing medical education with an in-depth scientific update.

The article systematically reviews the role of ¹⁸F-FDG PET/CT across the full clinical spectrum of head and neck squamous cell carcinoma (HNSCC):

• Initial staging and evaluation of occult primary tumors

• Assessment of cervical nodal disease, distant metastases, and synchronous malignancies

• Prognostic value of pre-treatment PET parameters

• PET/CT-guided radiation therapy planning and treatment adaptation

• Post-chemoradiotherapy assessment with high negative predictive value, helping reduce unnecessary neck dissections

• Emerging advances including radiomics, machine learning, PET/MRI, and non-FDG radiotracers

For imaging specialists and oncology professionals, this CME activity supports both clinical practice improvement and formal credit requirements.

Authors:

Carmelo Caldarella, Marina De Risi, Mariangela Massaccesi, Francesco Miccichè, Francesco Bussu, Jacopo Galli, Vittoria Rufini, Lucia Leccisotti

https://www.acapedia.com/article/18F-FDG-PET-CT-head-neck-carcinoma-evidence

Acapedia CME | Insights on 18F-FDG PET/CT in Head & Neck Carcinoma Earn CME credit with Acapedia! Explore comprehensive insights on 18F-FDG PET/CT in head and neck squamous cell carcinoma. Learn and earn today!

🧬 Chemotherapy & Biological Aging: Understanding the Epigenetic Impact

Chemotherapy remains a cornerstone of breast cancer treatment, yet its broader biological effects continue to be an important area of study. Research published in Epigenetics has examined how chemotherapy influences DNA methylation–based biological age, offering deeper insight into how cytotoxic therapies may interact with the ageing process.

Using peripheral blood samples from women undergoing breast cancer treatment, the study evaluated six well-established biological ageing markers—including GrimAge, PhenoAge, DunedinPACE, and telomere length—before and after the first cycle of chemotherapy.

📌 Highlighted Observations:

- Increases in several epigenetic age acceleration markers

- A measurable rise in the pace of ageing (DunedinPACE)

- Decreases in telomere length

- Findings remained consistent after adjusting for chronological age and race

These results contribute to the ongoing understanding that chemotherapy may influence pathways related to biological ageing—an important consideration for long-term survivorship planning and age-related health outcomes.

For clinicians, this article offers 1.0 AMA PRA Category 1 CME Credit™, as well as MOC or Patient Safety credit depending on specialty.

Acapedia CME | Chemotherapy's Impact on Biological Age in Breast Cancer Earn CME credit with Acapedia! Explore our research on chemotherapy's role in accelerating biological age in breast cancer patients. Read, learn, and earn today!

🌍 Advancing Diagnostics in Rural Africa with Handheld Ultrasound

A remarkable study highlights the power of handheld ultrasonography to support frontline clinicians in rural sub-Saharan Africa when diagnosing heart failure and pulmonary disease.

Conducted at a referral center in rural Tanzania, the study evaluated 438 patients with respiratory symptoms and compared lung ultrasound findings between:

🔹 Primary care clinicians using a handheld device

🔹 Expert board-certified sonographers using high-end machines

🔹 Senior physicians providing final diagnoses

Despite receiving just a few hours of focused training, clinicians achieved:

✅ 93% median agreement with expert sonographers on ultrasonographic findings

✅ 90% agreement on key diagnoses

✅ Substantial agreement with senior physicians for heart failure (κ = 0.69)

✅ Moderate agreement for tuberculosis (κ = 0.57)

While agreement for pneumonia remained low, the results strongly suggest that handheld ultrasound—paired with clinical examination—can significantly strengthen diagnostic capability where resources are limited.

Why it matters:

Handheld ultrasound continues to emerge as one of the most impactful tools for global health equity. It offers real-time insights, portability, and affordability—empowering clinicians in remote settings to identify critical conditions earlier and more accurately.

Study Authors:

Andrew Katende, Johanna Oehri, Victor Z Urio, Evance Mahundi, Lulu Wilson, Victor Myovela, Chipegwa Mlula, Christamonica Chitimbwa, Caspar Mbawala, Fanuel Faustine, Valentine Mteki, FR. WINFRID GINGO, Faraja Kitila, Ipyana Mwasongwe, Claudia Bucher, Luigia Elzi, James Okuma, Thomas Zoller, Daniel H Paris, Maja Weisser, Martin Rohacek

Interests: Focused ultrasound, pulmonary disease, heart failure, tuberculosis

CME: AMA PRA Category 1 Credit | Eligible for MOC or Patient Safety credit

Acapedia CME | Handheld Ultrasonography for Cardiac & Pulmonary Diseases Earn CME credits at Acapedia with this insightful article on the use of handheld ultrasonography for diagnosing cardiac and pulmonary diseases in rural Africa. Read now!

🔬 Revolutionizing Autoimmune Therapy Through Fc Engineering

A groundbreaking study published in Science by Andrew T. Jones, Alessandra E. Marino, Tetyana Martynyuk, Stylianos Bournazos, and Jeffrey Ravetch explores how fine-tuning antibody structure can drastically enhance therapeutic outcomes.

The research demonstrates that the anti-inflammatory activity of immunoglobulin G (IgG) is significantly amplified when type I and type II Fc receptors are co-engaged — specifically FcγRIIB and DC-SIGN.

By engineering a sialylated Fc fragment (V11 sFc) with enhanced affinity for the inhibitory receptor FcγRIIB, the team achieved comparable efficacy to intravenous immunoglobulin (IVIG) at 100× lower doses.

This discovery not only provides insight into the molecular mechanism of IVIG’s action but also paves the way for a new generation of anti-inflammatory biologics — more potent, accessible, and sustainable.

🧠 Key insights:

• Fc-engineered sialylated IgG shows 100-fold higher potency than standard IVIG.

• Co-engagement of FcγRIIB and DC-SIGN enhances IgG’s immunoregulatory activity.

• This dual-receptor interaction may redefine treatment paradigms for autoimmune disorders.

📄 Reference:

“The anti-inflammatory activity of IgG is enhanced by co-engagement of type I and II Fc receptors”

https://www.science.org/doi/10.1126/science.adv2927

The anti-inflammatory activity of IgG is enhanced by co-engagement of type I and II Fc receptors Intravenous immunoglobulin (IVIG) administered at high doses is used to treat a wide array of autoimmune diseases. Studies in murine models have identified that the anti-inflammatory activity of IVIG is dependent on sialylation of the N-linked glycan on ...

💡 Radiodermatitis and Fibrosis in Breast Radiation Therapy

Radiation therapy techniques have advanced with the goal of maintaining effective tumor control while minimizing skin toxicity.

This critical review analyzes how various radiation and fractionation methods affect the incidence and severity of radiodermatitis and fibrosis.

🔍 Highlights:

• IMRT shows lower acute toxicity compared to 3DCRT, improving treatment tolerance.

• Hypofractionation achieves equivalent efficacy and safety with fewer cases of radiodermatitis and fibrosis.

• Partial breast irradiation is linked to higher late toxicity and reduced local control.

• Sequential boost techniques increase the risk of fibrosis and radiodermatitis.

Intraoperative radiation therapy (IORT) offers strong local control with reduced late toxicity.

🏥 Clinical relevance:

The integration of IMRT and modified fractionation schedules has optimized both treatment efficiency and patient comfort—marking a major step toward safer, more tolerable breast radiotherapy.

📖 Reference: Sofiane Allali, YOULIA KIROVA

🎓 1.0 AMA PRA Category 1 CME Credit — qualifies for MOC or Patient Safety Credit depending on board requirements.

https://www.acapedia.com/article/radiodermatitis-fibrosis-breast-radiation-therapy-review

Acapedia CME | Radiodermatitis & Fibrosis in Breast Radiation A Review Earn CME credit with Acapedia! Read our comprehensive review on radiodermatitis and fibrosis in breast radiation therapy. Stay informed, improve patient care.

🎓 1.0 CME | Breast Cancer Screening Among Females With and Without Schizophrenia

A large Ontario-based study explored how breast cancer screening rates differ between women with and without schizophrenia, revealing important insights into healthcare access and equity.

📊 Among over 127,000 participants, only 69.3% of females with schizophrenia completed a mammogram within two years of turning 50, compared to 77.1% of those without schizophrenia.

💡 The analysis also showed that primary care payment models make a difference. Women cared for by physicians in Family Health Team models had higher screening rates than those in fee-for-service systems.

These findings emphasize the need to expand team-based, coordinated primary care to ensure better preventive care and early cancer detection among women living with schizophrenia.

Authors: Braden O’Neill, Abban Yusuf, Aisha Lofters, Anjie Huang, Ngozi Ekeleme, Tara Kiran, Michelle Greiver, Frank Sullivan, Paul Kurdyak

🏅 Accreditation: 1.0 AMA PRA Category 1 Credit™ | Eligible for MOC or Patient Safety credit

https://www.acapedia.com/article/breast-cancer-screening-schizophrenia-ontario

Acapedia CME | Breast Cancer Screening in Schizophrenia Patients Earn CME credits with Acapedia by understanding the impact of schizophrenia on breast cancer screening completion in Ontario. Read now!

🧬 Spatially mapping DLBCL’s immune microenvironments reveals targetable inflammatory niches

Nature Genetics (2025) — MD Anderson & collaborators

Using high-plex single-cell spatial transcriptomics (CosMx) and spatial proteomics (CODEX) across 78 DLBCL tumors, this study defines seven stereotyped cellular niches (CNs) that shape T-cell and tumor B-cell phenotypes via distinct neighbor interactions and signaling.

Key insights:

• Seven niches (e.g., T-cell–rich CN1, myeloid-rich CN3, tumor-B–dense CN5, diffuse CN6) organize how cells co-localize and communicate.

• Immune-privileged site (IPS) DLBCL (CNS/testis/eye): surprisingly robust T-cell infiltration with strong cytotoxic and proliferative signatures, yet co-inhibitory signaling (PD-1/PD-L1, LAG3, TIM3) → immunotherapy-amenable “inflammatory” niches.

• EBV-positive DLBCL: enriched T-cell and mixed niches; T cells show high cytotoxicity plus exhaustion, supporting checkpoint blockade, CAR-T, and bispecific strategies.

• Tumor-B–dense CN5: driven by the CXCL12–CXCR4 axis, high proliferation and BCL2 expression, leading to suppressed T-cell function—a rationale for CXCR4/BCL2-targeted therapies.

• Why spatial matters: Directly captures neighborhoods and ligand–receptor wiring that bulk RNA or deconvolution methods miss—unlocking new mechanistic and therapeutic insights.

Clinical & translational takeaways:

✅ Use spatial niche profiling to guide immunotherapy selection.

✅ Combine checkpoint targets (PD-1 + LAG3/TIM3) for IPS/EBV+ cases.

✅ Target CXCR4/BCL2 in dense tumor niches (CN5).

✅ Provide AI-ready spatial data to predict microenvironment features from H&E slides.

Yibo Dai, Atish Kizhakeyil, Dai Chihara, Xubin Li, Yunhe Liu, Tania Patricia Sainz Zuniga, Ashley Wilson, Jared Henderson, Daniil Vibe, Arman A Petrosyants, Connor Jacobson, Alexander Sarachakov, Krystle Nomie, Kirill Kryukov, Alexander Bagaev, Ayushi Chauhan, Jason Westin, MD MS FASCO, Christopher R. Flowers, MD, Francisco Vega, Linghua Wang & Michael Green

https://www.nature.com/articles/s41588-025-02353-5

Multi-modal spatial characterization of tumor immune microenvironments identifies targetable inflammatory niches in diffuse large B cell lymphoma - Nature Genetics Analysis of the immune microenvironment of diffuse B cell lymphomas using spatial transcriptomics, proteomics and genomics highlights discrete cellular niches with divergent patterns of cell–cell communication that contribute to the phenotypic heterogeneity of both tumor and immune cells.